Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SonaCare Medical
The proposed study is a prospective, non-randomized concurrently controlled study. The active treatment arm uses the HIFU procedure with the Sonablate device. The control arm uses the brachytherapy procedure. The safety and effectiveness of the Sonablate arm will be compared with the brachytherapy arm. The control arm of the study will be conducted at clinical sites different from the Sonablate arm.
Age
40–75
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
T1c or T2a carcinoma of the prostate confirmed by biopsy;
life expectancy of 5(five) years or more;
prostate biopsy with 10(ten) or more core biopsies;
Gleason score of 6(six) or less;
serum Prostate Specific Antigen (PSA) of 10(ten)ng/ml or less;
prostate volume of less than 40(Forty)cc;
distance from the Anterior capsule surface to the Posterior capsule surface (AP Diameter) of 40(Forty)cm or less;
informed consent for the treatment study through 24 months post-treatment follow-up
You may not be if
men who have had previous definitive treatment for prostate cancer;
evidence of metastatic disease and/or a previous positive bone-scan, previous diagnosis or treatment for cancer within the last 5(five) years;
prior hormonal therapy for prostate cancer (including bilateral orchiectomy);
inability to tolerate a transrectal ultrasound;
active urinary tract infection;
functional bladder problems;
prior significant rectal surgery;
intra-prostatic calcifications greater than 1(One)cm in diameter;
interest in future fertility;
prostatic surgery/procedure (except biopsy) within 1(One) year;
large median lobe of the prostate;
use of medications that can affect PSA within 2(Two) months (e.g. finasteride, saw palmetto);
current bladder cancer, urethral stricture, or bladder neck contracture;
urinary tract and/or rectal fistula;
rectal fibrosis/stenosis;
anomaly of the rectal anatomy or mucus membrane;
prostate seroma/abcess;
prostatitis;
compromised renal function or upper urinary tract disease secondary to urinary obstruction;
bleeding disorders/coagulopathy based on measures of PT and PTT;
implant in the prostate or within 1(One)cm of the prostate;
zip code of the primary residence of the subject is greater than 200(Two hundred) miles from the clinical site or transportation that would hinder the completion of the study
Clareo Health | Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
